Charles Schwab
CRVS icon

Charles Schwab’s Corvus Pharmaceuticals CRVS Stock Holding History

Charles Schwab’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Buy
208,119
+19,990
+11% +$277K ﹤0.01% 2645
2026
Q1 		$2.75M Buy
188,129
+16,956
+10% +$271K ﹤0.01% 2627
2025
Q4 		$1.32M Sell
171,173
-6,615
-4% -$52.2K ﹤0.01% 2838
2025
Q3 		$1.31M Buy
177,788
+15,967
+10% +$81.7K ﹤0.01% 2860
2025
Q2 		$647K Buy
161,821
+131,853
+440% +$480K ﹤0.01% 3039
2025
Q1 		$95.3K Hold
29,968
– – ﹤0.01% 3350
2024
Q4 		$160K Buy
29,968
+14,300
+91% +$107K ﹤0.01% 3351
2024
Q3 		$82.7K Hold
15,668
– – ﹤0.01% 3387
2024
Q2 		$28.5K Hold
15,668
– – ﹤0.01% 3566
2024
Q1 		$27.9K Hold
15,668
– – ﹤0.01% 3419
2023
Q4 		$27.6K Hold
15,668
– – ﹤0.01% 3457
2023
Q3 		$22.9K Hold
15,668
– – ﹤0.01% 3501
2023
Q2 		$35.9K Buy
+15,668
New +$32.5K ﹤0.01% 3471
2022
Q1 		– Sell
-11,217
Closed -$28K – 3592
2021
Q4 		$28K Hold
11,217
– – ﹤0.01% 3556
2021
Q3 		$55K Buy
+11,217
New +$33.2K ﹤0.01% 3441
2021
Q2 		– Sell
-13,830
Closed -$43K – 3439
2021
Q1 		$43K Buy
+13,830
New +$50K ﹤0.01% 3451
2019
Q2 		– Sell
-36,275
Closed -$146K – 3229
2019
Q1 		$146K Buy
36,275
+10,375
+40% +$43.8K ﹤0.01% 3063
2018
Q4 		$96K Hold
25,900
– – ﹤0.01% 3094
2018
Q3 		$223K Hold
25,900
– – ﹤0.01% 3063
2018
Q2 		$285K Buy
25,900
+8,400
+48% +$93.8K ﹤0.01% 2992
2018
Q1 		$202K Hold
17,500
– – ﹤0.01% 2991
2017
Q4 		$182K Hold
17,500
– – ﹤0.01% 2994
2017
Q3 		$279K Hold
17,500
– – ﹤0.01% 2903
2017
Q2 		$212K Buy
+17,500
New +$187K ﹤0.01% 3014

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Charles Schwab's CRVS Position: Q2 2026 in Review

Charles Schwab increased its Corvus Pharmaceuticals (CRVS) stake by 11% in Q2 2026, buying an estimated $277K and bringing the position to 208,119 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

Charles Schwab first reported a position in CRVS in Q2 2017 and has held it in 24 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Charles Schwab held 208,119 shares of Corvus Pharmaceuticals worth $3.11M as of Q2 2026.
  • Charles Schwab bought 19,990 Corvus Pharmaceuticals shares in Q2 2026, an estimated $277K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2645 holding.
  • Charles Schwab first reported a position in Corvus Pharmaceuticals in Q2 2017 and has held it in 24 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.